These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

390 related items for PubMed ID: 30010109

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Context-dependent miR-204 and miR-211 affect the biological properties of amelanotic and melanotic melanoma cells.
    Vitiello M, Tuccoli A, D'Aurizio R, Sarti S, Giannecchini L, Lubrano S, Marranci A, Evangelista M, Peppicelli S, Ippolito C, Barravecchia I, Guzzolino E, Montagnani V, Gowen M, Mercoledi E, Mercatanti A, Comelli L, Gurrieri S, Wu LW, Ope O, Flaherty K, Boland GM, Hammond MR, Kwong L, Chiariello M, Stecca B, Zhang G, Salvetti A, Angeloni D, Pitto L, Calorini L, Chiorino G, Pellegrini M, Herlyn M, Osman I, Poliseno L.
    Oncotarget; 2017 Apr 11; 8(15):25395-25417. PubMed ID: 28445987
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Patient-derived tumor xenograft model to guide the use of BRAF inhibitors in metastatic melanoma.
    Guerreschi P, Scalbert C, Qassemyar A, Kluza J, Ravasi L, Huglo D, Martinot-Duquennoy V, Formstecher P, Marchetti P, Mortier L.
    Melanoma Res; 2013 Oct 11; 23(5):373-80. PubMed ID: 23852164
    [Abstract] [Full Text] [Related]

  • 25. Differential inhibition of ex-vivo tumor kinase activity by vemurafenib in BRAF(V600E) and BRAF wild-type metastatic malignant melanoma.
    Tahiri A, Røe K, Ree AH, de Wijn R, Risberg K, Busch C, Lønning PE, Kristensen V, Geisler J.
    PLoS One; 2013 Oct 11; 8(8):e72692. PubMed ID: 24023633
    [Abstract] [Full Text] [Related]

  • 26. EPHA2 is a mediator of vemurafenib resistance and a novel therapeutic target in melanoma.
    Miao B, Ji Z, Tan L, Taylor M, Zhang J, Choi HG, Frederick DT, Kumar R, Wargo JA, Flaherty KT, Gray NS, Tsao H.
    Cancer Discov; 2015 Mar 11; 5(3):274-87. PubMed ID: 25542448
    [Abstract] [Full Text] [Related]

  • 27. T-Type Calcium Channels as Potential Therapeutic Targets in Vemurafenib-Resistant BRAFV600E Melanoma.
    Barceló C, Sisó P, Maiques O, García-Mulero S, Sanz-Pamplona R, Navaridas R, Megino C, Felip I, Urdanibia I, Eritja N, Soria X, Piulats JM, Penin RM, Dolcet X, Matías-Guiu X, Martí RM, Macià A.
    J Invest Dermatol; 2020 Jun 11; 140(6):1253-1265. PubMed ID: 31877318
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance.
    Das Thakur M, Salangsang F, Landman AS, Sellers WR, Pryer NK, Levesque MP, Dummer R, McMahon M, Stuart DD.
    Nature; 2013 Feb 14; 494(7436):251-5. PubMed ID: 23302800
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma.
    Kim A, Cohen MS.
    Expert Opin Drug Discov; 2016 Sep 14; 11(9):907-16. PubMed ID: 27327499
    [Abstract] [Full Text] [Related]

  • 40. BRAFi induced demethylation of miR-152-5p regulates phenotype switching by targeting TXNIP in cutaneous melanoma.
    Li K, Tang M, Tong S, Wang C, Sun Q, Lv M, Sun X, Wang T, Jin S.
    Apoptosis; 2020 Apr 14; 25(3-4):179-191. PubMed ID: 32056038
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 20.